Predictive Clinical and Biological Parameters in Gynecological Cancer
Launched by INSTITUT PAOLI-CALMETTES · Oct 30, 2013
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different factors that might help predict how gynecological cancers, like ovarian, endometrial, and cervical cancer, behave. Researchers are looking at things like genetics and proteins in the body to see if they can find patterns that help doctors understand these cancers better. The trial is currently recruiting female participants aged 18 and older who have a suspicion of having gynecological cancer and are willing to sign a consent form to take part.
If you join this study, you can expect to undergo tests that will help gather information about your condition. It’s important to note that this trial is not for those who are dealing with an emergency or those who have been diagnosed with cancers other than the specified gynecological types. This research aims to improve how doctors can predict and treat these cancers in the future, ultimately benefiting patients like you.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • gynecological cancer suspicion
- • age \> 18
- • signed informed consent
- Exclusion Criteria:
- • - emergency
- • Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
About Institut Paoli Calmettes
Institut Paoli-Calmettes (IPC) is a leading cancer research and treatment center located in Marseille, France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. With a multidisciplinary approach, IPC integrates cutting-edge research, education, and clinical services to enhance cancer prevention, diagnosis, and treatment. The institute is committed to fostering collaboration among researchers, healthcare professionals, and patients, aiming to translate scientific discoveries into effective therapeutic strategies. As a recognized institution in the field of oncology, IPC plays a pivotal role in shaping the future of cancer care and improving patient outcomes through rigorous and ethical clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials